About
DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries. DEINOVE has developed a unique and comprehensive expertise in the...
DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries. DEINOVE has developed a unique and comprehensive expertise in the field of rare bacteria that it can decipher, culture, and optimize to disclose unsuspected possibilities and induce them to produce biobased molecules with activities of interest on an industrial scale. To do so, DEINOVE has been building and documenting since its creation an unparalleled biodiversity bank that it exploits thanks to a unique technological platform in Europe. DEINOVE is organized around two areas of expertise: ANTIBIOTICS, Next--generation anti-infectives: DEINOVE is preparing to enter a first antibiotic candidate into Phase II. The Company is also pursuing the systematic exploration of biodiversity to supply its portfolio with new leads, drawing notably on partnerships with Naicons and bioMérieux (AGIR program supported by Bpifrance). BIOACTIVES, Active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: DEINOVE already markets a first innovative active ingredient, a second in partnership with Greentech, while two others are in development with Oléos (Hallstar Group). It also runs a program in animal nutrition with Groupe Avril. Several other partnerships are also being developed. Within the Euromedecine science park located in Montpellier, DEINOVE employs 62 employees, mainly researchers, engineers, and technicians, and has filed more than 260 patent applications internationally. The Company has been listed on EURONEXT GROWTH® since April 2010.
  • 18
    Feb
    19
    News Release
    DEINOVE announces its financial calendar for 2019
  • 31
    Jan
    19
    News Release
    Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficileinfections, with a key partner
  • 10
    Jan
    19
    News Release
    A new website to highlight DEINOVE’s disruptive innovation strategy
  • 6
    Dec
    18
    Equity Research
    Deinove SA (EPA:ALDEI) Research Update
  • 5
    Dec
    18
    Company Presentation
    Deinove life genius delivered
  • 30
    Nov
    18
    Corporate Update
    Interim financial report – Half-year 2018
  • 23
    Nov
    18
    News Release
    Deinove will market a 2nd proprietary carotenoid-based cosmetic active ingredient in 2019
  • 21
    Nov
    18
    News Release
    DEINOVE confirms its financing options by renewing its equity line
  • 24
    Oct
    18
    News Release
    DEINOVE to collaborate with CALIBR to explore the anti-infectious potentials of its bacterial collection
  • 15
    Oct
    18
    Company Presentation
    Investor Presentation: Life genius delivered
  • 2
    Oct
    18
    News Release
    Strategic partnership between DEINOVE and SOLVAY for the marketing of phytoene in North America and Asia
  • 28
    Sep
    18
    News Release
    Deinove is the regional winner of the ‘PME Bougeons-nous’ awards in the ‘creative business’ category
  • 27
    Sep
    18
    News Release
    Deinove 2018 half-year consolidated results: strengthened financial situation, substantial progress in both areas of business
  • 26
    Sep
    18
    Equity Research
    Deinove SA (EPA:ALDEI) Research Update
  • 13
    Sep
    18
    News Release
    Strategic partnership between DEINOVE and UNIVAR for the distribution of Phyt-N-Resist® in the EMEA zone
  • 9
    Jul
    18
    News Release
    Deinove awarded by the bioeconomy community
  • 28
    Jun
    18
    News Release
    Deinove enters into collaboration with bioMérieux to discover new antibiotics
  • 19
    Jun
    18
    Equity Research
    Deinove SA (EPA:ALDEI) Research Initiation
  • 19
    Jun
    18
    News Release
    Arrowhead initiates coverage on Deinove in the United States
  • 15
    Jun
    18
    News Release
    DEINOVE: Successful Capital Increase of € 8.5 Million
  • 14
    Jun
    18
    News Release
    DEINOVE announces the launch of a capital increase through an accelerated book building
  • 30
    May
    18
    News Release
    DEINOVE and OLEOS expand their collaboration with the support of the Occitanie Region
  • 23
    May
    18
    News Release
    DEINOVE General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM
  • 22
    May
    18
    News Release
    DEINOVE COLOR2B project: confirmed progress and outlook
  • 30
    Apr
    18
    Company Presentation
    DEINOVE Presentation to Investors - Update on Antibiotic strategy
  • 16
    Apr
    18
    News Release
    DEINOVE and GREENTECH announce the launch of HEBELYS®, the first cosmetic active ingredient resulting from their collaboration
  • 13
    Apr
    18
    News Release
    DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound
  • 10
    Apr
    18
    News Release
    DEINOVE introduces Phyt-n-Resist®, the first pure phytoene for skincare
  • 29
    Mar
    18
    News Release
    DEINOVE 2017: ambitions confirmed, milestones reached, and financial results in line with the development strategy
  • 22
    Mar
    18
    News Release
    DEINOVE expands its innovative antibiotic portfolio by signing a license option agreement with REDX PHARMA
  • 8
    Mar
    18
    News Release
    DEINOVE collaborates with NAICONS to discover new antibiotics in the frame of the AGIR project
  • 26
    Feb
    18
    News Release
    DEINOVE announces the success of its cosmetic active ingredient’s production process industrialization
  • 19
    Feb
    18
    News Release
    DEINOVE announces its financial calendar for 2018
  • 30
    Jan
    18
    News Release
    DEINOVE and Hallstar’s Oléos, partners in the development of a new cosmetic active ingredient
  • 18
    Dec
    17
    News Release
    DEINOVE launches the industrial production of its first carotenoid
  • 20
    Nov
    17
    News Release
    DEINOVE and GREENTECH are making progress in the co-development of their cosmetic active ingredient
  • 31
    Oct
    17
    Company Presentation
    DEINOVE Presentation to Investors, October 2017
  • 23
    Oct
    17
    News Release
    DEINOVE confirms the launch of its first cosmetic active ingredient during the first half of 2018 and targets the very dynamic segment of anti-aging skincare
  • 28
    Sep
    17
    News Release
    DEINOVE 2017 half-year consolidated results: stability of net loss major progress on R&D programs in health, nutrition and cosmetics
  • 28
    Sep
    17
    Corporate Update
    DEINOVE Interim financial report – Half-year 2017
  • 12
    Sep
    17
    News Release
    The AGIR project carried out by the DEINOVE group is granted €14.6 million by the ‘Investments for the Future’ Program (IFP) operated by Bpifrance to develop new antibiotics
  • 24
    Jul
    17
    News Release
    DEINOVE strengthens its Business Development activity with the arrival of Sébastien Enault
  • 5
    Jul
    17
    News Release
    DEINOVE: the industrialization process of the carotenoids program enters phase II
  • 31
    May
    17
    News Release
    DEINOVE and FLINT HILLS RESOURCES enter the second stage of their partnership in animal feed
  • 23
    May
    17
    News Release
    DEINOVE welcomes its new Director of R&D, Georges Gaudriault
  • 16
    May
    17
    News Release
    DEINOVE Shareholders’ meeting of May 16, 2017: Hervé BRAILLY joins the Board of Directors
  • 30
    Mar
    17
    Corporate Update
    DEINOVE Annual Financial Report 2016